Drug Trial Radar · NCT05541276
MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in Children
Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
676
Planned (sponsor's estimate)
Start
Jan 21, 2025
Primary completion
Mar 1, 2027
Study completion Apr 1, 2027
Sponsor
- Lead sponsor
- Arash AfshariAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sygehus Lillebaelt; University of Copenhagen; Copenhagen Trial Unit, Center for Clinical Intervention Research
- First posted
- Sep 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Postoperative agitation and emergence delirium describe a spectrum of symptoms of early postoperative negative behavior, in which the child experiences a variety of behavioral disturbances including crying, thrashing, and disorientation during early awakening from anaesthesia. The symptoms are common with a reported incidence of approximately 25%. Some clinical trials have studied the effect of prophylactic oral melatonin for reducing the risk of emergence agitation in children, some finding a considerable dose-response effect. Melatonin has a low bio-availability of approximately 15 %. The safety of exogenous melatonin for pediatric patients has been studied with no apparent serious adverse effects, even at repeated short-term use of high doses of intravenous melatonin. The aim of this clinical trial is to investigate the prophylactic effects and safety of intravenous melatonin administered intraoperatively for prevention of postopreative agitation and emergence delirium in children after an elective surgical procedure. The study is designed as a randomised, double-blind, placebo-controlled clinical trial.
Conditions
- Emergence Delirium
Interventions
MelatoninDrug
Melatonin for injection 1 mg/mL
Isotonic sodium chloride solutionDrug
Sodium chloride 0.9 % for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of emergence agitationTime frame: Up to approximately 4 hours corresponding to stay in Post-Anesthetic Care Unit (PACU).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Anesthesiology, Juliane Marie Center, Rigshospitalet
Copenhagen, Capital Region, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.